Mersana Therapeutics, Inc. Common Stock
Symbol: MRSN (NASDAQ)
9.29
▼ (-7.56%) -0.760
Company Description:
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
Key Stats
- Today's Open: $9.99
- Today's High: $10.02
- Today's Low: $8.815
- Today's Volume: 88.77K
- Yesterday Close: $10.05
- Yesterday High: $10.5111
- Yesterday Low: $10.02
- Yesterday Volume: 15.58K
- Last Min Volume: 10
- Last Min High: $9.29
- Last Min Low: $9.29
- Last Min VWAP: $9.29
Company Profile
- Name: Mersana Therapeutics, Inc. Common Stock
- Website: https://www.mersana.com
- Listed Date: 2017-06-28
- Location: CAMBRIDGE, MA
- Market Status: Active
- CIK Number: 0001442836
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $50.16M
- Round Lot: 100
- Outstanding Shares: 4.99M
- Asset Type: CS
RECENT FILINGS FOR MRSN
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-15 | 4 | View |
| 2025-09-05 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-13 | 10-Q | View |
| 2025-08-13 | 8-K | View |
| 2025-07-24 | 8-K | View |
| 2025-07-17 | SCHEDULE 13G/A | View |
| 2025-07-03 | 8-K | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 8-K | View |
| 2025-06-02 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-15 | SCHEDULE 13G | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
Latest News on MRSN